Safety & Side Effects
GI tolerability, serious adverse events, thyroid warnings, and contraindications
The Safety Profile
More receptor targets means more potential side effects. Retatrutide's Phase 2 data showed a familiar GI side effect profile -- nausea, diarrhea, vomiting -- that was largely manageable with slow titration. But three-receptor agonism also raises unique monitoring questions around thyroid C-cells, pancreatitis, and hepatic effects. This unit gives you the complete safety picture from published data.
GI Side Effects
Nausea, diarrhea, vomiting, and constipation rates by dose tier.
Dose Tolerability
Discontinuation rates, dose titration strategy, and tolerability across tiers.
Serious Adverse Events
SAE rates, hospitalizations, and treatment-emergent events of special interest.
Thyroid C-Cell Warning
The GLP-1 class-wide thyroid concern and what the preclinical data shows.
Contraindications
Who should not use GLP-1 class drugs and monitoring recommendations.